0      0


AM22-54-O - AM22-54-O: (On-Demand) Innovations in Blood Storage to Prevent Red Blood Cell Damage (Enduring)


‐ Nov 7, 2022 6:00pm

Expiration Date: Dec 31, 2024


Credits: None available.

Ongoing research continues to both expand the understanding of the needs of transfusion recipients and to provide opportunities to better meet these needs through developing new red cell (RBC) products. This session will summarize the unmet needs of transfusion recipients, and new approaches being pursued. The role of oxidative damage during storage, an important factor of why RBCs degrade and the potential for improved outcomes will be explored. Attendees completing this session will understand new RBC storage systems removing oxygen or using new additives to enhance RBC transfusion therapy.
Outline:

Speaker 1 - Topic 1: Oxygen Degradation of the RBC with current storage methods

  • Define the oxidative damage that RBC experience after collection and storage and how it impairs its functionality
  • Recognize the changes in RBC quality caused by oxidative damage as measured by current techniques.
  • Question the effects of oxidative damage and the role it plays on RBC quality, specifically in assessing successful patient treatment and expected outcomes.
  • Hypothesize potential opportunities (ie: hypoxic blood or additive solutions) for both short and long term efficacy, to improve RBC quality and resulting patient outcomes.

Speaker 2 - Topic 2: Unmet needs and problems to be solved with current RBC transfusions: 

  • Benefits of Improved oxygen delivery and prolonged RBC lifespan for acute and chronic transfusions, emphasizing the improvement of clinical outcomes with improved oxygen delivery
  • Improvements in blood processing and storage - novel methods to preserve and store RBC ( AS7, Hemanext, and Rejuvasol) with improved in vitro properties
  • Development of new RBC therapy products with augmented efficacy and/or safety profiles. Presentation will describe the early clinical trials that are getting underway to demonstrate efficacy and safety improvements.

All relevant financial relationships have been mitigated.


Learning Objectives:

  • Summarize unmet needs of RBC transfusion recipients
  • Define the oxidative damage that occurs during RBC storage and its impairment of functionality
  • Recognize the changes in RBC quality caused by oxidative damage as measured by current techniques
  • Hypothesize potential opportunities for short and long term RBC storage to improve RBC quality and patient outcomes

Speaker(s):

Moderator(s):

Disclosures

  • Paul Ness, MD:

    Hemanext: Consultant, Member, Scientific Advisory Board, Board of Directors

  • Steven Spitalnik, MD, PhD:
    Hemanext: Consultant Hemanext: Member, Scientific Advisory Board Hemanext: Member, Scientific Advisory Board TCIP, Inc.: Stock Shareholder (self-managed) Tioma, Inc.: Consultant Worldwide Initiative for Rh Disease Eradication (WIRE): Executive Director of this non-profit organization Ferrous Wheel Consultants, LLC: Full-time/Part-time Employee
  • Jose Cancelas, MD, PhD:
    Hemanext: Consultant Hemanext: Member, Scientific Advisory Board Hemanext: Grant/Research Support (Secondary Investigators need not disclose) Hemanext: Member, Scientific Advisory Board Cerus Co.: Grant/Research Support (Secondary Investigators need not disclose) Cellphire Therapeutics: Grant/Research Support (Secondary Investigators need not disclose) TerumoBCT: Consultant TerumoBCT: Grant/Research Support (Secondary Investigators need not disclose) Fresenius-Kabi: Grant/Research Support (Secondary Investigators need not disclose) Cytosorbents: Consultant Cytosorbents: Grant/Research Support (Secondary Investigators need not disclose) Vascular Solutions/Teleflex: Consultant Vascular Solutions/Teleflex: Grant/Research Support (Secondary Investigators need not disclose) Platefuse Inc: Stock Shareholder (self-managed) MEQU-Univ. of Florida: Grant/Research Support (Secondary Investigators need not disclose) US DoD-Westat: Grant/Research Support (Secondary Investigators need not disclose) National Institutes of Health: Grant/Research Support (Secondary Investigators need not disclose) National Institutes of Health: Honoraria

Tags:

new innovations new techniques and new technologies collections and product manufacturing transfusion medicine clinical practices red cells cell biology immunology and biochemistry basic and preclinical

By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available


AM22-54-O: (On-Demand) Innovations in Blood Storage to Prevent Red Blood Cell Damage (Enduring) Evaluation